why are there so many glp 1 drugs GLP-1 Medications: Everything You Need to Know The GLP-1 Agonists and Obesity:

doi: 10.1056/NEJMoa2403347 [DOI] [PubMed] [Google Scholar] 257

This comparison is not meant to discourage herbal use but to establish evidence-based context

Orforglipron, developed by Eli Lilly, is the first non-peptide oral GLP-1 agonist, achieving up to 1.8% HbA1c reduction and 1012% body-weight loss in Phase 3 trials

Obesity, currently defined as a body mass index (BMI) of 30 kg/m 2 or greater, affects 800 million people worldwide [1]

The two medicines act differently to manage blood sugar

When you look past consumer packaged goods (CPG), the impact of GLP-1 drugs is less easy to predict but arguably even more disruptive